Table 1. Clinical diagnostic value of CSF chemokine biomarkers for neurosyphilis.
| Biomarker | AUC* | 95% CI# | Optimal cut-off | Sensitivity | Specificity |
|---|---|---|---|---|---|
| CSF CXCL13 | 0.940 | 0.913–0.967 | 256.4 pg/ml | 85.4% | 89.1% |
| CSF CXCL8 | 0.899 | 0.863–0.935 | 48.1 pg/ml | 79% | 90.1% |
| CSF CXCL10 | 0.915 | 0.881–0.950 | 163.1 pg/ml | 79.6% | 91.1% |
| CSF/Serum ratio of CXCL13 | 0.963 | 0.942–0.983 | 4.36 | 86.6% | 99% |
| CSF/Serum ratio of CXCL8 | 0.846 | 0.799–0.892 | 10.3 | 79% | 73.3% |
| CSF/Serum ratio of CXCL10 | 0.926 | 0.893–0.959 | 1.02 | 86% | 92.1% |
| Model1 | 0.949 | 0.926–0.972 | 1.1 | 90.4% | 82.9% |
| Model2 | 0.966 | 0.945–0.986 | 2.23 | 90.4% | 93.7% |
| CSF VDRL | 0.952 | 0.925–0.980 | 1 | 90.4% | 100% |
These biomarkers to diagnosis of neurosyphilis was evaluated by receiver-operating characteristic (ROC) curves.
AUC is the percentage of randomly drawn pairs for which the test is correct.
#CI, confidence interval.